Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
32.02
-0.44 (-1.36%)
At close: Dec 5, 2025, 4:00 PM EST
32.00
-0.02 (-0.06%)
After-hours: Dec 5, 2025, 6:05 PM EST
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Viridian Therapeutics stock ranges from a low of $26 to a high of $61. The average analyst price target of $39 forecasts a 21.80% increase in the stock price over the next year.
Price Target: $39.00 (+21.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 6 | 5 |
| Buy | 6 | 5 | 5 | 5 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | +28.04% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +40.54% | Nov 6, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $61 | Strong Buy | Reiterates | $61 | +90.51% | Nov 4, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | +12.43% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
80.26M
from 302.00K
Increased by 26,477.48%
Revenue Next Year
85.26M
from 80.26M
Increased by 6.23%
EPS This Year
-4.15
from -3.07
EPS Next Year
-3.89
from -4.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 132.0M | 217.7M | ||||
| Avg | 80.3M | 85.3M | ||||
| Low | 289,100 | 2.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 43,608.6% | 171.2% | ||||
| Avg | 26,477.5% | 6.2% | ||||
| Low | -4.3% | -96.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.52 | -2.45 | ||||
| Avg | -4.15 | -3.89 | ||||
| Low | -4.66 | -4.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.